Tirzepatide Use Is Associated with Reduced Risk of Carpal Tunnel Syndrome in Overweight and Obese Adults

Tirzepatide use was associated with a lower risk of developing carpal tunnel syndrome than both GLP-1 receptor agonists and other anti-obesity medications in overweight or obese adults. Compared with other anti-obesity medications, tirzepatide was also associated with fewer carpal tunnel surgeries.

Journal article — Retrospective cohort with target trial emulation. Population: Adults aged ≥18 years who were overweight or obese and initiated tirzepatide, GLP-1RAs, or other anti-obesity medications in the TriNetX US Collaborative Network. Interventions: Tirzepatide.

After propensity score matching, well-balanced cohorts were achieved. Tirzepatide use was associated with a significantly lower risk of carpal tunnel syndrome compared with GLP-1RAs (HR 0.82; 95% CI 0.71-0.95), with no significant difference in carpal tunnel syndrome surgery. Compared with other anti-obesity medications, tirzepatide was associated with reduced risks of both carpal tunnel syndrome (HR 0.75; 95% CI 0.65-0.85) and carpal tunnel syndrome surgery (HR 0.64; 95% CI 0.44-0.94).

For researchers studying tirzepatide, this paper offers real-world evidence that tirzepatide may be associated with lower carpal tunnel syndrome risk than other anti-obesity medications and GLP-1RAs, possibly pointing to metabolic or neuroprotective effects. It does not establish a causal mechanism, and because it is observational and lacks reported dosing and follow-up details, it should not be read as proof of a direct protective effect.

Key findings

• Tirzepatide use was associated with a significantly lower risk of carpal tunnel syndrome compared with GLP-1RAs (HR 0.82; 95% CI 0.71-0.95).
• No significant difference in carpal tunnel syndrome surgery was seen between tirzepatide and GLP-1RAs.
• Tirzepatide use was associated with a reduced risk of carpal tunnel syndrome compared with other anti-obesity medications (HR 0.75; 95% CI 0.65-0.85).
• Tirzepatide use was associated with a reduced risk of carpal tunnel syndrome surgery compared with other anti-obesity medications (HR 0.64; 95% CI 0.44-0.94).

Limitations

• Retrospective observational design cannot establish causality.
• Propensity score matching only controls for measured confounders, so residual confounding is possible.
• Reliance on electronic health-record/claims data may be subject to coding or misclassification errors.
• The abstract does not report sample size, follow-up duration, or exact matching variables.

The record

• Journal: Clinical pharmacology and therapeutics
• Published: 2026-08-10
• PMID: 42572932 — DOI: 10.1002/cpt.70440
• Author countries: Germany, Taiwan

Peptide profiles: Tirzepatide.

All indexed evidence: Tirzepatide trials & papers.

Related studies: Peripheral nerve complications from medications utilised for weight loss: a systematic…, Incretin-Based Therapies in Doxorubicin-Induced Cardiotoxicity: A Systematic Review of…, Effects of GLP-1 Receptor Agonists and Dual GIP/GLP-1 Receptor Agonists on Inflammatory…, Comparative effects of drugs for adults with overweight or obesity: systematic review….